<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109429">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02107664</url>
  </required_header>
  <id_info>
    <org_study_id>2013/1126</org_study_id>
    <nct_id>NCT02107664</nct_id>
  </id_info>
  <brief_title>The Palliative Radiotherapy And Inflammation Study - PRAIS</brief_title>
  <acronym>PRAIS</acronym>
  <official_title>The Palliative Radiotherapy And Inflammation Study: Palliative Radiotherapy of Bone Metastasis. Classification, Inflammatory Biomarkers, and Longitudinal Clinical Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European palliative care research centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alesund Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <authority>Norway:National Committee for Medical and Health Research Ethics</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiation therapy (RT) is one of the primary treatments for bone cancer pain due to
      metastatic cancer disease. About 6 of 10 patients obtain pain relief from RT. There are no
      established predictors that can be used to select patients that respond to RT. This raises
      the need to identify potential clinical characteristics and biomarkers that may better
      select patients for RT. A similar argument can be stated for the development of cachexia;
      there are currently no predictors that can identify patients who will develop cachexia later
      in the cancer disease trajectory. Cancer symptoms can be related to inflammation. Both pain,
      cachexia and depression are associated with inflammation in experimental and preclinical
      studies . Still, the clinical data on the relationship between inflammation and pain or
      cachexia are sparse. This is especially true for longitudinal follow-up studies.

      This study will include 1000 adult patients in a multicenter, multinational longitudinal
      observation study of patients who receive radiation therapy for bone cancer pain.
      Demographic data, clinical variables, genetic biomarkers and inflammatory substances will be
      assessed before start of RT. The primary analysis in the study is to identify potential
      predictors for pain relief from RT. During follow up the study will also explore for
      predictors for development of cachexia and which inflammatory substances that are associated
      with changes in pain intensity, depression and development of cachexia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Pain response</measure>
    <time_frame>3 - 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete response implies a numeric rate scale (NRS) worst pain of zero at the treated site on an 11-point rating scale, with no concomitant increase in analgesic intake.
Partial response is defined as either i) pain reduction of two or more at the treated site on the 11-point NRS worst pain rating scale together with no increase in analgesic intake, or ii) reduction in analgesic intake of at least 25 per cent from baseline without an increase in pain score at the treated site.
An &quot;intermediate response&quot; category represents any response other than complete or partial response or pain progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cachexia</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cachexia defined as a) Weight loss &gt;5% over past 6 months (in absence of simple starvation); or b) body mass index (BMI) &lt;20 and any degree of weight loss &gt;2%; or c) Appendicular skeletal muscle index consistent with sarcopenia (males &lt;7・26 kg/m2; females &lt;5・45 kg/m2) and any degree of weight loss &gt;2%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Depression symptoms last 2 weeks scored i patient Health Questionnaire (PHQ) - 9.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Inflammatory Biomarkers</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in inflammatory biomarkers during longitudinal follow-up in relation to change in pain, depression and cachexia.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <condition>Bone Neoplasms</condition>
  <arm_group>
    <arm_group_label>Radiation therapy for bone cancer pain</arm_group_label>
    <description>The group includes all cancer diagnoses, and different fractions of RT planned.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Palliative RT for bone cancer pain</intervention_name>
    <arm_group_label>Radiation therapy for bone cancer pain</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Genetic and Cytokine Analyses
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to palliative RT for bone cancer pain
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Verified cancer diagnosis (based on radiological, histological, cytological or
             operative evidence). Those with hematological malignancies are also eligible.

          -  Bone metastasis verified either by bone x-ray, bone scan, computer tomography (CT) or
             magnetic resonance imaging (MRI)

          -  Patients that are about to undergo radiotherapy with palliative intent for painful
             bone metastasis

          -  Radiotherapy should be administered within one week after baseline observations are
             obtained

          -  Age ≥18 years

          -  Patient is able to comply with trial procedures.

        Exclusion criteria:

          -  Pathological fracture in long bones (e.g femora or humeral shaft fractures)

          -  Patients not consenting to participate in the study

          -  On-going RT or RT administered within the last 4 weeks

          -  Patients who are not able to follow the trial procedures

          -  Previous participation in this study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pål Klepstad, phd md</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pål Klepstad, prof.</last_name>
    <phone>+47 72575709</phone>
    <email>pal.klepstad@ntnu.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ragnhild Habberstad, md</last_name>
    <phone>+ 47 72827705</phone>
    <email>ragnhild.hansdatter.habberstad@stolav.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept of Oncology, Oslo Universitetssykehus</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dept of Oncology, St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pål Klepstad, prof. md</last_name>
      <phone>+47 72575709</phone>
      <email>pal.klepstad@ntnu.no</email>
    </contact>
    <contact_backup>
      <last_name>Ragnhild H Habberstad, md</last_name>
      <phone>+47 72827705</phone>
      <email>ragnhild.hansdatter.habberstad@stolav.no</email>
    </contact_backup>
    <investigator>
      <last_name>Trude Camilla Frøseth</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ragnhild Habberstad, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pål Klepstad, md phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Oncology, Ålesund sjukehus</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gunnar Indrebø</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Cachexia</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Depression</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
